Electronic Nose Analysis May Predict Response to Anti-PD-1 Therapy in NSCLC

WEDNESDAY, Sept. 18, 2019 -- For patients with non-small cell lung cancer (NSCLC), responders and nonresponders can be differentiated by a metal oxide semiconductor electronic nose (eNose) analysis of exhaled breath before starting antiprogrammed...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news